Treatment of cytomegalovirus retinitis with dihydroxy propoxymethyl guanine. 1986

A G Palestine, and G Stevens, and H C Lane, and H Masur, and L S Fujikawa, and R B Nussenblatt, and A H Rook, and J Manischewitz, and B Baird, and M Megill

Eight patients with cytomegalovirus retinitis in one or both eyes were treated with 9-(1,3 dihydroxy 2-propoxymethyl) guanine. Of the 14 eyes with retinitis, eight demonstrated more than 90% resolution, four had partial improvement, one failed to respond, and one could not be evaluated. Two of the eight patients had chemotherapy-induced immunosuppression and had ocular remissions for at least several months. The remaining six patients had AIDS or probable AIDS and relapsed in five weeks or less after discontinuation of therapy. Dihydroxy propoxymethyl guanine appears to be effective biologically in treating human cytomegalovirus retinitis without the development of unacceptable side effects but a single course of therapy is not capable of eradicating the virus.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000212 Acyclovir A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. Acycloguanosine,9-((2-Hydroxyethoxy)methyl)guanine,Aci-Sanorania,Acic,Aciclobeta,Aciclostad,Aciclovir,Aciclovir Alonga,Aciclovir-Sanorania,Acifur,Acipen Solutab,Acivir,Activir,Acyclo-V,Acyclovir Sodium,Antiherpes Creme,Avirax,Cicloferon,Clonorax,Cusiviral,Genvir,Herpetad,Herpofug,Herpotern,Herpoviric,Isavir,Laciken,Mapox,Maynar,Milavir,Opthavir,Supraviran,Viclovir,Vipral,Virax-Puren,Virherpes,Virmen,Virolex,Virupos,Virzin,Wellcome-248U,Zoliparin,Zovirax,Zyclir,aciclovir von ct,Aci Sanorania,Aciclovir Sanorania,Acyclo V,Alonga, Aciclovir,Sodium, Acyclovir,Solutab, Acipen,Virax Puren,ViraxPuren,Wellcome 248U,Wellcome248U
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A G Palestine, and G Stevens, and H C Lane, and H Masur, and L S Fujikawa, and R B Nussenblatt, and A H Rook, and J Manischewitz, and B Baird, and M Megill
May 1986, American journal of ophthalmology,
A G Palestine, and G Stevens, and H C Lane, and H Masur, and L S Fujikawa, and R B Nussenblatt, and A H Rook, and J Manischewitz, and B Baird, and M Megill
April 1986, American journal of ophthalmology,
A G Palestine, and G Stevens, and H C Lane, and H Masur, and L S Fujikawa, and R B Nussenblatt, and A H Rook, and J Manischewitz, and B Baird, and M Megill
October 1986, American journal of ophthalmology,
A G Palestine, and G Stevens, and H C Lane, and H Masur, and L S Fujikawa, and R B Nussenblatt, and A H Rook, and J Manischewitz, and B Baird, and M Megill
February 1987, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie,
A G Palestine, and G Stevens, and H C Lane, and H Masur, and L S Fujikawa, and R B Nussenblatt, and A H Rook, and J Manischewitz, and B Baird, and M Megill
June 1987, American journal of ophthalmology,
A G Palestine, and G Stevens, and H C Lane, and H Masur, and L S Fujikawa, and R B Nussenblatt, and A H Rook, and J Manischewitz, and B Baird, and M Megill
January 1987, American journal of ophthalmology,
A G Palestine, and G Stevens, and H C Lane, and H Masur, and L S Fujikawa, and R B Nussenblatt, and A H Rook, and J Manischewitz, and B Baird, and M Megill
February 1988, Transplantation proceedings,
A G Palestine, and G Stevens, and H C Lane, and H Masur, and L S Fujikawa, and R B Nussenblatt, and A H Rook, and J Manischewitz, and B Baird, and M Megill
June 1988, Transplantation,
A G Palestine, and G Stevens, and H C Lane, and H Masur, and L S Fujikawa, and R B Nussenblatt, and A H Rook, and J Manischewitz, and B Baird, and M Megill
August 1986, Annals of internal medicine,
A G Palestine, and G Stevens, and H C Lane, and H Masur, and L S Fujikawa, and R B Nussenblatt, and A H Rook, and J Manischewitz, and B Baird, and M Megill
April 1986, Annals of internal medicine,
Copied contents to your clipboard!